Trials / Completed
CompletedNCT04338724
A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors
A Phase I, Open-Label, Dose-Escalation Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- CStone Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, dose escalation phase I study to evaluate the clinical safety, tolerability in subjects with advanced solid tumors, and to establish the Maximum Tolerated Dose (MTD#, if any). This study is composed of two dose level: 1 and 3 mg/kg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS1002 | The dose levels will be escalated following a modified 3+3 dose escalation scheme. |
Timeline
- Start date
- 2019-12-27
- Primary completion
- 2020-09-21
- Completion
- 2020-09-21
- First posted
- 2020-04-08
- Last updated
- 2021-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04338724. Inclusion in this directory is not an endorsement.